In final draft guidance published today (7 March), NICE has recommended omalizumab (Xolair, Novartis Pharmaceuticals UK) as an option for treating severe, persistent allergic asthma in adults, ...
Bedfont ® outlines key updates and offers support for healthcare professionals navigating the changes. Bedfont ® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results